Otherwise healthy m 65 yr. On active surveillance PSA 5.8. MRI's all clear. Two fusion biopsies. In 2018, Gleason 3+3, one core only, low volume. 2019 Gleason 3+4. One core only, same localized area, 40% vol.
Considering RP, hi energy brachytherapy, and SBRT.
Just received Oncotype (high risk) and Genomics DX (intermediate risk) test results.
How should I factor the genome test results in the consideration of 1) staying on active surveillance, and 2) RP v. brachytherapy or SBRT?